NEW YORK (PIX11) – It is being called a game-changer in curing some of the world’s most crippling diseases and conditions. Technology developed by FibroBiologics is already proving in small trials to ...
HOUSTON, Feb. 20, 2024 /PRNewswire/ -- FibroBiologics (Nasdaq: FBLG) ("FibroBiologics") is a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development ...
FibroBiologics, Inc. Announces Investor Webinar on Innovative Fibroblast-Based Cell Therapy Platform
FibroBiologics, Inc., a clinical-stage biotechnology company focused on developing therapies for chronic diseases through fibroblasts, announced an investor webinar scheduled for July 10, 2025, at ...
A Quick Take On FibroBiologics, Inc. FibroBiologics, Inc. (FBLG) has filed to raise in a Direct Listing of its common stock, according to an SEC S-1 registration statement. The clinical-stage firm is ...
At the summit, Mr. O’Heeron will address an expert audience of researchers, biotech executives, and policy leaders on the next frontier of longevity science, including breakthroughs in cellular ...
This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. NEW YORK (PIX11) – It is being called a game ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results